在过去的十年中，表皮生长因子受体（EGFR）靶向疗法改变了晚期实体瘤患者的治疗格局。尽管取得了这些进展，抗 EGFR 疗法的耐药性仍然是一个重大的临床挑战。虽然细胞自主耐药机制已有充分记录，但它们并没有完全阐明耐药性的复杂性。癌症相关成纤维细胞 (CAF) 是肿瘤微环境 (TME) 内的关键介质，已成为癌症进展和化疗耐药的关键参与者。最近的证据表明 CAF 对抗 EGFR 疗法具有抵抗力，这表明它们可能会损害治疗效果。这篇综述综合了当前的数据，强调了 CAF 在耐药发病机制中的关键作用，并总结了最近针对 CAF 的治疗策略。我们强调挑战并主张探索 CAF 作为一种潜在的双重目标方法。版权所有 © 2024。由 Elsevier Ltd 出版。

Over the last decade, epidermal growth factor receptor (EGFR)-targeted therapies have transformed the treatment landscape for patients with advanced solid tumors. Despite these advances, resistance to anti-EGFR therapies is still a significant clinical challenge. While cell-autonomous mechanisms of resistance are well-documented, they do not fully elucidate the complexity of drug resistance. Cancer-associated fibroblasts (CAFs), key mediators within the tumor microenvironment (TME), have emerged as pivotal players in cancer progression and chemoresistance. Recent evidence implicates CAFs in resistance to anti-EGFR therapies, suggesting they may undermine treatment efficacy. This review synthesizes current data, highlighting the critical role of CAFs in resistance pathogenesis and summarizing recent therapeutic strategies targeting CAFs. We underscore the challenges and advocate for the exploration of CAFs as a potential dual-targeted approach.Copyright © 2024. Published by Elsevier Ltd.